Clinical Trial Update: Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating tumor necrosis factor inhibition for focal segmental glomerulosclerosis and treatment-resistant minimal change disease has c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Segmental Glomerulosclerosis
• Minimal Change Disease

Drugs mentioned

• Tumor necrosis factor inhibitor (unspecified)

Snippet

Sponsor: University of Michigan | Conditions: FSGS, MCD | Phase 2 | Status: COMPLETED | Results posted: 2024-10-30